{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:46:20Z","timestamp":1792784780454,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00228-026-04208-2","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:44:49Z","timestamp":1792723489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing between public safety signals and label strengthening in targeted oncology therapies"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7308-2069","authenticated-orcid":false,"given":"Xiaogao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"4208_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J (2020) Antibody-drug conjugates: a comprehensive review. Mol Cancer Res 18:3\u201319. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0582","journal-title":"Mol Cancer Res"},{"key":"4208_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"4208_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S (2023) Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther 8:262. https:\/\/doi.org\/10.1038\/s41392-023-01469-6","journal-title":"Signal Transduct Target Ther"},{"key":"4208_CR4","doi-asserted-by":"publisher","first-page":"pkad069","DOI":"10.1093\/jncics\/pkad069","volume":"7","author":"Y Suzuki","year":"2023","unstructured":"Suzuki Y, Zhou S, Ota Y et al (2023) Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis. JNCI Cancer Spectr 7:pkad069. https:\/\/doi.org\/10.1093\/jncics\/pkad069","journal-title":"JNCI Cancer Spectr"},{"key":"4208_CR5","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H et al (2022) Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 7:100554. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100554","journal-title":"ESMO Open"},{"key":"4208_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/ICU.0000000000001063","volume":"35","author":"RF Marshall","year":"2024","unstructured":"Marshall RF, Xu H, Berkenstock M (2024) Ocular toxicities associated with antibody drug conjugates. Curr Opin Ophthalmol 35:494\u2013498. https:\/\/doi.org\/10.1097\/ICU.0000000000001063","journal-title":"Curr Opin Ophthalmol"},{"key":"4208_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"4208_CR8","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2004) Pharmacovigilance planning E2E. https:\/\/database.ich.org\/sites\/default\/files\/E2E_Guideline.pdf. Accessed 1 Oct 2026"},{"key":"4208_CR9","unstructured":"European Medicines Agency (2017) Guideline on good pharmacovigilance practices (GVP), Module IX - signal management (Rev 1). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf. Accessed 16 Apr 2026"},{"key":"4208_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in Pharmacovigilance (READUS-PV): development and statement. Drug Saf 47:575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9","journal-title":"Drug Saf"},{"key":"4208_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in Pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf 47:585\u2013599. https:\/\/doi.org\/10.1007\/s40264-024-01423-7","journal-title":"Drug Saf"},{"key":"4208_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4208_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4208_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13:519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4208_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4208_CR16","doi-asserted-by":"publisher","first-page":"e071752","DOI":"10.1136\/bmj-2022-071752","volume":"379","author":"MM Dhodapkar","year":"2022","unstructured":"Dhodapkar MM, Shi X, Ramachandran R et al (2022) Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study. BMJ 379:e071752. https:\/\/doi.org\/10.1136\/bmj-2022-071752","journal-title":"BMJ"},{"key":"4208_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH (2013) Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 93:539\u2013546. https:\/\/doi.org\/10.1038\/clpt.2013.24","journal-title":"Clin Pharmacol Ther"},{"key":"4208_CR18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/pds.5073","volume":"29","author":"M Rosenberg","year":"2020","unstructured":"Rosenberg M, Sheehan S, Zhou E et al (2020) FDA postmarketing safety labeling changes: what have we learned since 2010 about impacts on prescribing rates, drug utilization, and treatment outcomes. Pharmacoepidemiol Drug Saf 29:1022\u20131029. https:\/\/doi.org\/10.1002\/pds.5073","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4208_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40264-016-0409-x","volume":"39","author":"KB Hoffman","year":"2016","unstructured":"Hoffman KB, Dimbil M, Tatonetti NP, Kyle RF (2016) A pharmacovigilance signaling system based on FDA regulatory action and post-marketing adverse event reports. Drug Saf 39:561\u2013575. https:\/\/doi.org\/10.1007\/s40264-016-0409-x","journal-title":"Drug Saf"},{"key":"4208_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40264-015-0358-9","volume":"39","author":"L McCormack","year":"2016","unstructured":"McCormack L, Lefebvre RC, Bann C, Taylor O, Rausch P (2016) Consumer understanding, preferences, and responses to different versions of drug safety messages in the United States: a randomized controlled trial. Drug Saf 39:171\u2013184. https:\/\/doi.org\/10.1007\/s40264-015-0358-9","journal-title":"Drug Saf"},{"key":"4208_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.amjopharm.2012.05.002","volume":"10","author":"ZA Marcum","year":"2012","unstructured":"Marcum ZA, Vande Griend JP, Linnebur SA (2012) FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 10:264\u2013271. https:\/\/doi.org\/10.1016\/j.amjopharm.2012.05.002","journal-title":"Am J Geriatr Pharmacother"},{"key":"4208_CR22","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1001\/jama.2017.5150","volume":"317","author":"NS Downing","year":"2017","unstructured":"Downing NS, Shah ND, Aminawung JA et al (2017) Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 317:1854\u20131863. https:\/\/doi.org\/10.1001\/jama.2017.5150","journal-title":"JAMA"},{"issue":"2","key":"4208_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jamainternmed.2025.6566","volume":"186","author":"H Doernberg","year":"2026","unstructured":"Doernberg H, Wallach JD, Jeffery MM, Mooghali M, Ramachandran R, Ross JS (2026) Postmarket Drug Safety\u2013Related Actions Before and After the US Food and Drug Administration Amendments Act. JAMA Intern Med 186(2):233\u2013242. https:\/\/doi.org\/10.1001\/jamainternmed.2025.6566","journal-title":"JAMA Intern Med"},{"key":"4208_CR24","doi-asserted-by":"publisher","first-page":"j3837","DOI":"10.1136\/bmj.j3837","volume":"358","author":"SR Mostaghim","year":"2017","unstructured":"Mostaghim SR, Gagne JJ, Kesselheim AS (2017) Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study. BMJ 358:j3837. https:\/\/doi.org\/10.1136\/bmj.j3837","journal-title":"BMJ"},{"key":"4208_CR25","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1200\/JCO.2017.77.5593","volume":"36","author":"D Shepshelovich","year":"2018","unstructured":"Shepshelovich D, Tibau A, Goldvaser H et al (2018) Postmarketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials. J Clin Oncol 36:1798\u20131804. https:\/\/doi.org\/10.1200\/JCO.2017.77.5593","journal-title":"J Clin Oncol"},{"key":"4208_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40264-021-01142-3","volume":"45","author":"D Croteau","year":"2022","unstructured":"Croteau D, Pinnow E, Wu E, Mu\u00f1oz M, Bulatao I, Dal Pan G (2022) Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration. Drug Saf 45:169\u2013180. https:\/\/doi.org\/10.1007\/s40264-021-01142-3","journal-title":"Drug Saf"},{"key":"4208_CR27","unstructured":"U.S. Food and Drug Administration (2026) Drug adverse event overview. https:\/\/open.fda.gov\/apis\/drug\/event\/. Accessed 16 Apr 2026"},{"key":"4208_CR28","unstructured":"Food US, Administration D (2026) How to use the drug adverse event endpoint. https:\/\/open.fda.gov\/apis\/drug\/event\/how-to-use-the-endpoint\/. Accessed 16 Apr 2026"},{"key":"4208_CR29","unstructured":"National Library of Medicine (2026) DailyMed. https:\/\/dailymed.nlm.nih.gov\/dailymed\/. Accessed 16 Apr 2026"},{"key":"4208_CR30","unstructured":"National Library of Medicine (2026) Application development support: web services. https:\/\/dailymed.nlm.nih.gov\/dailymed\/app-support-web-services.cfm. Accessed 16 Apr 2026"},{"key":"4208_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147:573\u2013577. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010","journal-title":"Ann Intern Med"},{"key":"4208_CR32","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"4208_CR33","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L et al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33:1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"4208_CR34","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA et al (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9:e002435. https:\/\/doi.org\/10.1136\/jitc-2021-002435","journal-title":"J Immunother Cancer"},{"key":"4208_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/17425255.2019.1574744","volume":"15","author":"JJ Jennings","year":"2019","unstructured":"Jennings JJ, Mandaliya R, Nakshabandi A, Lewis JH (2019) Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin Drug Metab Toxicol 15:231\u2013244. https:\/\/doi.org\/10.1080\/17425255.2019.1574744","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4208_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"TB Peeraphatdit","year":"2020","unstructured":"Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR (2020) Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology 72:315\u2013329. https:\/\/doi.org\/10.1002\/hep.31227","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"4208_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V (2018) Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 19(Suppl 1):31\u201339. https:\/\/doi.org\/10.1007\/s40257-018-0384-3","journal-title":"Am J Clin Dermatol"},{"key":"4208_CR38","doi-asserted-by":"publisher","first-page":"107778","DOI":"10.1016\/j.isci.2023.107778","volume":"26","author":"Z Fu","year":"2023","unstructured":"Fu Z, Gao C, Wu T, Wang L, Li S, Zhang Y et al (2023) Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates. iScience 26:107778. https:\/\/doi.org\/10.1016\/j.isci.2023.107778","journal-title":"iScience"},{"key":"4208_CR39","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cpt.2023.11.005","volume":"2","author":"Y Li","year":"2024","unstructured":"Li Y, Zhao J, Wang Y, Xu Y, Li R, Zhao Y et al (2024) Common endocrine system adverse events associated with immune checkpoint inhibitors. Cancer Pathog Ther 2:164\u2013172. https:\/\/doi.org\/10.1016\/j.cpt.2023.11.005","journal-title":"Cancer Pathog Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04208-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04208-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04208-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:02:11Z","timestamp":1792782131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04208-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4208"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04208-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used only public, non-interventional, de-identified data sources and publicly accessible document histories; institutional review board approval was not required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used DeepSeek-V4 for language polishing and improving readability. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of this manuscript.","order":5,"name":"Ethics","label":"Use of AI tools","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"277"}}